Our pipeline forms a robust portfolio of investigational
therapies in varied stages of clinical development.
- What is PentambodyTM?
- Penta amino acid mutated bispecific antibody
PENTAMBODY is a next generation, bispecific antibody platform technology developed by Beijing Hanmi Pharmaceutical Co., a subsidiary of Hanmi. This platform allows the antibody to simultaneously bind two different targets for both immuno-oncology therapy and targeted therapy. It possesses natural IgG-like antibody structure, therefore demonstrating good stability and other important natural IgG-like biophysical properties. Multiple bispecific antibodies using PENTAMBODY are being developed by Hanmi.
- Next generation bispecific antibody platform technology
- Next generation bispecific antibody
Maximize Therapeutic Synergies
Immunotherapy and Targeted Therapy
Enhanced Stability and Manufacturability
- Seeking collaboration opportunities
Pentambody + Novel target
Pentambody Platform Technology Licensing